Compare GRPN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | ABUS |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 887.5M |
| IPO Year | 2011 | 2008 |
| Metric | GRPN | ABUS |
|---|---|---|
| Price | $18.80 | $4.25 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.67 | N/A |
| AVG Volume (30 Days) | 994.5K | ★ 6.7M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | ★ $2,843,877,000.00 | $14,083,000.00 |
| Revenue This Year | $4.06 | $1,208.75 |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | ★ N/A | $4.98 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $9.17 | $3.50 |
| 52 Week High | $29.90 | $5.45 |
| Indicator | GRPN | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 32.80 |
| Support Level | $15.92 | $4.17 |
| Resistance Level | $18.85 | $4.57 |
| Average True Range (ATR) | 0.97 | 0.18 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 25.67 | 20.00 |
Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.